In a recent issue of Oncotarget [1], Nakayama et al. showed the anti-tumor activity of selinexor, an inhibitor of exportin 1, against a wide variety of sarcoma preclinical models, including several pathological subtypes of soft tissue sarcomas (STS). This evidence concerns the gene XPO1 and sarcoma.